Search Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseIron OverloadSubgroupICD10MeSHHemosiderosisMyelodysplastic SyndromesThalassemiaSequenceChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceDeferasiroxDeferiproneDeferoxamineSupportive substanceDeferasiroxDeferiproneDeferoxamineSupportive substanceDeferasiroxDeferiproneDeferoxamineSupportive substanceDeferasiroxDeferiproneDeferoxamineNo. Substances1Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationSecond lineTherapy phaseTherapy intentionsupportiveRisksArthalgiaConstipationDiarrheaHeadacheHepatotoxicityIncrease AminotransferasesMyalgiasNauseaNephrotoxicityNeutropeniaProteinuriaPyrexiaRashUpper Respiratory Tract Infection only studiesPublicationAuthorAngelucci EMeerpohl JJRoberts DJ Takatoku M DiseaseEisenüberadung beim MDS (IPSS low/intermediate risk I)Eisenüberladung bei IPSS low- or intermediate-1–Risiko MDSEisenüberladung bei Thalassämietransfusionsbedingte Eisenüberadung bei beta-Thalassämietransfusionsbedingte Eisenüberladung bei beta-ThalassämieOriginGerman Cochrane Centre, Medical Center - University of Freiburg, Freiburg, GermanyHematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genova, TELESTO trialJichi Medical University, Tochigi, JapanNHS Blood and Transplant, Oxford, UKSystematic Review Initiative, NHS Blood and Transplant, Oxford, UKProtocols in Revision 5 protocols foundProtocols under revision.Deferasirox 14, Beta Thalassemia (PID1837 V1.0)Deferasirox 14, Myelodysplastic Syndrome (PID1840 V1.0)Deferiprone 25, Beta Thalassemia (PID1841 V1.0)Deferoxamine 25, Beta Thalassemia (PID1838 V1.0)Deferoxamine 25, Myelodysplastic Syndrome (PID2301 V1.0)
